Flexion Therapeutics Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Net loss
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation
Amortization of right-of-use assets
Stock-based compensation expense
Other non-cash charges
Provision for inventory
Non-cash interest expense
Amortization (accretion) of premium (discount) on marketable securities
Loss on disposal of fixed assets
Loss from debt extinguishment
Amortization of debt discount and debt issuance costs
Premium paid on securities purchased

Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other current liabilities
Net cash used in operating activities
Deferred revenue
Lease liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Change in restricted cash
Proceeds from sale of fixed assets
Purchases of marketable securities
Sale and redemption of marketable securities
Net cash used in investing activities
Net cash (used in) provided by investing activities

Cash flows from financing activities
Proceeds from the issuance of 2024 convertible notes
Proceeds from borrowings under term loan
Payment of debt issuance costs
Proceeds from revolving line of credit
Repayments of revolving line of credit
Proceeds from the offering of common stock
Payments of public offering costs
Payments on notes payable
Proceeds from issuance of notes payable
Proceeds from the exercise of stock options
Proceeds from employee stock purchase plan
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Net cash provided by (used in) financing activities

Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Supplemental disclosures of cash flow information
Cash paid for interest
Non-cash investing and financing activities
Right-of-use asset obtained in exchange for operating lease obligation
Portion of debt proceeds allocated to equity component
Purchases of property and equipment in accounts payable and accrued expenses
Public offering costs in accounts payable and accrued expenses

Comments